Literature DB >> 17037407

[A case of pulmonary adenocarcinoma accompanied by minimal change nephrotic syndrome, antiphospholipid syndrome and warm-type autoimmune hemolytic anemia].

Shinji Miyajima1, Yoshio Taguchi, Eisaku Tanaka, Tetsuro Inoue, Minoru Sakuramoto, Masayoshi Minakuchi, Yuji Maeda, Ko Maniwa, Kiminobu Tanizawa, Masaki Okamoto, Tomoshi Takeda.   

Abstract

A 49-year-old man was urgently admitted due to edema in both leg and left toe pain. A chest radiograph revealed a solitary nodule in the right lung field. Detailed investigations including bronchoscopy and renal biopsy led to a simultaneous diagnosis of clinical stage IIIB pulmonary adenocarcinoma, minimal change nephrotic syndrome, antiphospholipid syndrome, and warm-type autoimmune hemolytic anemia. Prednisolone was administered for nephrotic syndrome, antiphospholipid syndrome and warm-type autoimmune hemolytic anemia, and 6 courses of chemotherapy with 70Gy radio-therapy were performed. The pulmonary nodule significantly decreased in size and the other three autoimmune diseases appeared to be well-controlled. Thirteen months after admission, multiple brain metastases developed along with worsening antiphospholipid syndrome symptoms including lupus anticoagulant. Following whole-brain irradiation, the brain metastases decreased in size and antiphospholipid syndrome symptoms improved. Thirty-nine months after the initial visit, the primary lung cancer, its brain metastasis and the 3 other autoimmune diseases appeared to be well-controlled. The temporal correlation of the lung cancer and the three autoimmune diseases suggests the latter may be paraneoplastic syndrome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17037407

Source DB:  PubMed          Journal:  Nihon Kokyuki Gakkai Zasshi        ISSN: 1343-3490


  1 in total

1.  Paraneoplastic Evans syndrome in a patient with adenocarcinoma of the lung: A case report.

Authors:  Hong Yu; Rong Fu; Huaquan Wang; Hui Liu; Zonghong Shao
Journal:  Thorac Cancer       Date:  2016-11-16       Impact factor: 3.500

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.